Products Affected - Description

• • Saxenda subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 5 count, NDC 00169-2800-15
  • Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00169-4060-12
  • Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00169-4060-13

Reason for the Shortage

• • Novo Nordisk did not provide a reason for the shortage of Victoza.
  • Novo Nordisk has Saxenda on shortage due to increased demand.
  • Teva launched the authorized generic of liraglutide in late-June 2024.

Available Products

• • Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00480-3667-20
  • Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00480-3667-22

• • Novo Nordisk has Victoza 6 mg/mL 3 mL pens in 2 and 3 count presentations on back order and the company estimates a release date in mid-July 2024.
  • Novo Nordisk has Saxenda 6 mg/mL 3 mL pens available in limited supply. This situation is expected to continue indefinitely.